SNOA: תחזית צמיחת רווח נקי למניה לשנה הבאה Sonoma Pharmaceuticals Inc.

High competition in dermatology and reliance on distributors create revenue risks, as evidenced by shifting analyst estimates for EPS growth, where the metric stands at 0.00. Sonoma Pharmaceuticals (SNOA) maintains stability through transparent management focused on innovation. A flawless brand image and patient loyalty to hypochlorous acid-based products provide additional support.
פילוחי מדדים ואנליטיקה של חברת Sonoma Pharma (SNOA)

This earnings per share growth forecast for Sonoma Pharmaceuticals (SNOA) reflects market expectations for EPS dynamics, measuring the growth rate of net income per share. The stability of this indicator confirms the sustainable expansion of Microcyn product lines into new markets, although tight monetary conditions may compress multiples, limiting final returns given a conservative pipeline.